

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Eric S. Lander, Michele Cargill, James S. Ireland, Stacey Bolk, George Q. Daley

and Jeanette J. McCarthy

Application No.:

09/657,472

Group Art Unit: 1634

Filed:

September 7, 2000

Examiner:

J.E. Souaya

Confirmation No.:

1705

(Filed after payment of issue fee)

Title:

SINGLE NUCLEOTIDE POLYMORPHISMS IN GENES

CERTIFICATE OF MAILING							
I hereby certify that this correspondence is being deposited with the United							
States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, P.O. Box 2327,							
A-II-man VA 22200							
on 21403 Hula Septtean							
Date Signature							
PAULA DEPETERU							
Typed or printed name of person signing certificate							

## SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

**Assistant Commissioner for Patents** P.O. Box 2327 Arlington, VA 22202 Sir: This Information Disclosure Statement is submitted: under 37 CFR 1.129(a), or (First/Second submission after Final Rejection) under 37 CFR 1.97(b), or [] (Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination). under 37 CFR 1.97(c) together with either: a Statement under 37 CFR 1.97(e), as checked below, or [ ] a \$180.00 fee under 37 CFR 1.17(p), or (After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first) under 37 CFR 1.97(d) together with: [] a Statement under 37 CFR 1.97(e), as checked below, and a \$180.00 fee under 37 CFR 1.17(p), or (Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee) [] under 37 CFR 1.97(i):

Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.

Staten	ner	it Un	ger 3/C	CFR 1.97(e)					
[]	Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or								
[]	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.								
Staten	ner	it Und	<u>der 37 (</u>	(Patent Term Adjustment) Applies to original applications (other than design) filed on or after May 29, 2000					
[ ]	Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.								
[X]	Enclosed herewith is form PTO-1449:								
	[]	X]	Сору	of the cited reference is enclosed.					
	[	1 .	Applic	of cited references are enclosed except those entered in prior application, U.S. ation No. [ ], to which priority under 35 U.S.C. 120 is claimed. [The earlier ation contains copies of the cited references.]					
]	[	]	The lis	sted references were cited in the enclosed International Search Report in a rpart foreign application.					
	)	The "cunder 3	oncise explanation" requirement (non-English references) for reference(s) [ ] 37 CFR 1.98(a)(3) is satisfied by:						
			[]	the explanation provided on the attached sheet.					
			[]	the explanation provided in the Specification.					
			[]	submission of the enclosed International Search Report.					
			[]	submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.					
			[]	the enclosed English language abstract.					

[]	Applic	ant requests that the following	non-published pending applic	cations be considered:					
Examiner's Initials									
		U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]					
		U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]					
		U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]					
		Examiner	Date	_					
	[ ] A copy of each above-cited application, including the current claims, is enclosed.								
	[ ]	A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed.							
The E	xaminė nces we	r is requested to return a copy or considered with the next offi	f the above list of pending ap ce communication.	plications indicating which					
It is re	equestec	I that the information disclosed	herein be made of record in t	his application.					
Metho	od of pa	yment:							
.[X]	A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.								
[]	Please	ase charge Deposit Account 08-0380 in the amount of \$[ ]. A copy of this Statement is losed.							
[X]	Pleas	e charge any deficiency in fees	and credit any overpayment to	o Deposit Account 08-0380.					
			Respectfully submitted,						
	HAMILTON, BROOK, SMITH & REYNOLDS, P.C.								
Lisa M. Treannie Registration No.: 41,368 Telephone: (978) 341-0036 Facsimile: (978) 341-0136									
		A 01742-9133							
Dated: 2/14/03									

							- oneec	1 01 1			
PTO-14	E			ATTORNEY DOCKET NO. 2825.1027-001	APPLICATION OP/65						
		MATION DISCLOSURE C S IN AN APPLICATION		APPLICANT Eric S. Lander et al.							
FEB ?		February 11, 2003 Several sheets if necessity		FILING DATE 09/07/00	CONFIRMATION NO. GROUP 1705 1634						
Y O TR	VDEMIN			PATENT DOCUMENTS	1						
	<del>-</del> -	T	0.5.	PAIBNI DOCUMENTS	<del></del>						
EXAM- INER INI- TIAL		DOCUMENT NU	MBER	ISSUE DATE / NAME PUBLICATION DATE							
	·						· · · · · · · · · · · · · · · · · · ·				
						<del>.</del>					
	<del>                                     </del>										
	┼	ļ									
	<b> </b>										
	<u> </u>		<del> </del>	·							
	<b></b> -		-7-1		<del> </del>						
	├	121	<del></del>		ļ						
	<u> </u>		<del></del>		<u>'</u>						
•											
	·		FORBIG	IN PATENT DOCUMENTS	L						
		DOCUMENT NUMBER DATE		COUNTRY	CLASS	SUB- CLASS	Transi Yes	ATION NO			
	L					L					
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)											
	Kalka, C., et al., "Novel Genes Containing the Thrombospondin Type 1 Domain Suppress the Development of Angiogenesis in an in-vivo Model of Peripheral Vascular Ischemia," Circulation, American Heart Association, Abstract No. 3825 from the 71st Scientific Sessions, Dallas, Texas, (November 8-11, 1998).										
EXAMIN	ER		<del></del>	DATE CONSIDERED							
								Ħ			